Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
- Peter Lynch
What is insider trading>>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Proteostasis Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
74373B109
(CUSIP Number)
N/A
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ¨ | Rule 13d-1(b) |
| ¨ | Rule 13d-1(c) |
| x | Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 74373B109 | 13G | Page 2 of 14 Pages |
| 1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
HealthCare Ventures VIII, L.P. | ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x 1
| ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
| ||
|
NUMBER OF |
5 |
SOLE VOTING POWER
0 | |
|
SHARES BENEFICIALLY OWNED BY |
6 |
SHARED VOTING POWER
0 | |
|
EACH REPORTING PERSON |
7 |
SOLE DISPOSITIVE POWER
0 | |
|
WITH
|
8 |
SHARED DISPOSITIVE POWER
0 | |
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 | ||
| 10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% | ||
| 12 |
TYPE OF REPORTING PERSON*
PN | ||
< div align="LEFT">
1 This Schedule 13G is being filed jointly by the Reporting Persons, as hereinafter defined. Such Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
| CUSIP No. 74373B109 | 13G | Page 3 of 14 Pages |
| 1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
HealthCare Partners VIII, L.P. | ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x See Footnote 1 | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
| ||
|
NUMBER OF |
5 |
SOLE VOTING POWER
0 | |
|
SHARES BENEFICIALLY OWNED BY |
6 |
SHARED VOTING POWER
0 | |
|
EACH REPORTING PERSON |
7 |
SOLE DISPOSITIVE POWER
0 | |
|
WITH
|
8 |
SHARED DISPOSITIVE POWER
0 | |
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 | ||
| 10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% | ||
| 12 |
TYPE OF REPORTING PERSON*
PN | ||
| CUSIP No. 74373B109 | 13G | Page 4 of 14 Pages |
| 1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
HealthCare Partners VIII, LLC | ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x See Footnote 1 | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
| ||
|
NUMBER OF |
5 |
SOLE VOTING POWER
0 | |
|
SHARES BENEFICIALLY OWNED BY |
6 |
SHARED VOTING POWER
0 | |
|
EACH REPORTING PERSON |
7 |
SOLE DISPOSITIVE POWER
0 | |
|
WITH
|
8 |
SHARED DISPOSITIVE POWER
0 | |
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 | ||
| 10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% | ||
| 12 |
TYPE OF REPORTING PERSON*
OO | ||
| CUSIP No. 74373B109 | 13G | Page 5 of 14 Pages |
| 1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
James H. Cavanaugh, Ph.D. | ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x See Footnote 1 | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION United States
| ||
|
NUMBER OF |
5 |
SOLE VOTING POWER
0 | |
|
SHARES BENEFICIALLY OWNED BY |
6 |
SHARED VOTING POWER
0 | |
|
EACH REPORTING PERSON |
7 |
SOLE DISPOSITIVE POWER
0 | |
|
WITH
|
8 |
SHARED DISPOSITIVE POWER
0 | |
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 | ||
| 10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% | ||
| 12 |
TYPE OF REPORTING PERSON*
IN | ||
| CUSIP No. 74373B109 | 13G | Page 6 of 14 Pages |
| 1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Christopher Mirabelli, Ph.D. | ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x See Footnote 1 | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION United States
| ||
|
NUMBER OF |
5 |
SOLE VOTING POWER
3,813 | |
|
SHARES BENEFICIALLY OWNED BY |
6 |
SHARED VOTING POWER
0 | |
|
EACH REPORTING PERSON |
7 |
SOLE DISPOSITIVE POWER
3,813 | |
|
WITH
|
8 |
SHARED DISPOSITIVE POWER
0 | |
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,813 | ||
| 10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% | ||
| 12 |
TYPE OF REPORTING PERSON*
IN | ||
| CUSIP No. 74373B109 | 13G | Page 7 of 14 Pages |
| 1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Harold R. Werner | ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x See Footnote 1 | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION United States
| ||
|
NUMBER OF |
5 |
SOLE VOTING POWER
0 | |
|
SHARES BENEFICIALLY OWNED BY |
6 |
SHARED VOTING POWER
0 | |
|
EACH REPORTING PERSON |
7 |
SOLE DISPOSITIVE POWER
0 | |
|
WITH
|
8 |
SHARED DISPOSITIVE POWER
0 | |
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 | ||
| 10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% | ||
| 12 |
TYPE OF REPORTING PERSON*
IN | ||
| CUSIP No. 74373B109 | 13G | Page 8 of 14 Pages |
| 1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
John W. Littlechild | ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x See Footnote 1 | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION United States
| ||
|
NUMBER OF |
5 |
SOLE VOTING POWER
0 | |
|
SHARES BENEFICIALLY OWNED BY |
6 |
SHARED VOTING POWER
0 | |
|
EACH REPORTING PERSON |
7 |
SOLE DISPOSITIVE POWER
0 | |
|
WITH
|
8 |
SHARED DISPOSITIVE POWER
0 | |
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 | ||
| 10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% | ||
| 12 |
TYPE OF REPORTING PERSON*
IN | ||
| CUSIP No. 74373B109 | 13G | Page 9 of 14 Pages |
| 1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Augustine Lawlor | ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x See Footnote 1 | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION United States
| ||
|
NUMBER OF |
5 |
SOLE VOTING POWER
0 | |
|
SHARES BENEFICIALLY OWNED BY |
6 |
SHARED VOTING POWER
0 | |
|
EACH REPORTING PERSON |
7 |
SOLE DISPOSITIVE POWER
0 | |
|
WITH
|
8 |
SHARED DISPOSITIVE POWER
0 | |
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 | ||
| 10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% | ||
| 12 |
TYPE OF REPORTING PERSON*
IN | ||
| CUSIP No. 74373B109 | 13G | Page 10 of 14 Pages |
Item 1.
| (a) | Name of Issuer |
Proteostasis Therapeutics, Inc.
| (b) | Address of Issuer’s Principal Executive Offices |
200 Technology Square, 4th Floor
Cambridge, Massachusetts 02139
Item 2.
| (a) | Name of Person Filing |
HealthCare Ventures VIII, L.P. (“HCVVIII”)
HealthCare Partners VIII, L.P. (“HCPVIII”)
HealthCare Partners VIII, LLC (“HCP VIII LLC”)
James H. Cavanaugh, Ph.D. (“Cavanaugh”)
Christopher Mirabelli, Ph.D. (“Mirabelli”)
Harold R. Werner (“Werner”)
John W. Littlechild (“Littlechild”)
Augustine Lawlor (“Lawlor”)(collectively, the “Reporting Persons”)
See attached Exhibit A, which is a copy of their agreement in writing to file this statement on behalf of each of them. 1
| (b) | Address of Principal Business Office or, if none, Residence |
The business address for HCVVIII, HCPVIII, HCP VIII LLC, Drs. Cavanaugh and Mirabelli and Messrs. Werner, Littlechild and Lawlor is 47 Thorndike Street, Suite B1-1, Cambridge, Massachusetts 02141.
| (c) | Citizenship |
HCVVIII and HCPVIII are limited partnerships organized under the laws of the State of Delaware. HCP VIII LLC is a limited liability company organized under the laws of the State of Delaware. Drs. Cavanaugh and Mirabelli and Messrs. Werner, Littlechild, and Lawlor are each United States citizens.
1 Drs. Cavanaugh and Mirabelli and Messrs. Werner, Littlechild and Lawlor are the Managing Directors of HCP VIII LLC. HCP VIII LLC is the General Partner of HCPVIII, which is the General Partner of HCVVIII, the record holder of the securities.
| CUSIP No. 74373B109 | 13G | Page 11 of 14 Pages |
| (d) | Title of Class of Securities |
Common Stock, $0.001 par value per share (the “Common Stock”)
| (e) | CUSIP Number |
74373B109
| Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: NOT APPLICABLE. |
| (a) | ¨ | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). |
| (b) | ¨ | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). |
| (c) | ¨ | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). |
| (d) | ¨ | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). |
| (e) | ¨ | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
| (f) | ¨ | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
| (g) | ¨ | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); |
| (h) | ¨ | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
| (i) | ¨ | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
| (j) | ¨ | A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); |
| (k) | ¨ | Group, in accordance with §240.13d-1(b)(1)(ii)(K). |
If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________________.
| Item 4. | Ownership. |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
| (a) | Amount beneficially owned: |
As of February 21, 2017, each of HCVVIII, HCPVIII, HCP VIII LLC, Dr. Cavanaugh and Messrs. Werner, Littlechild and Lawlor owned 0 shares of the Common Stock. Dr. Mirabelli owned 3,813 shares of the Common Stock.
| (b) | Percent of class: Based on 24,960,243 shares outstanding as of November 8, 2016, as reported in the Issuer’s Form 10-Q for the quarter ended September 30, 2016 and filed with the Securities and Exchange Commission on November 10, 2016 each of the Reporting Persons other than Dr. Mirabelli owned 0% and Dr. Mirabelli owned less than .1% |
| (c) | Number of shares as to which the person has: |
| CUSIP No. 74373B109 | 13G | Page 12 of 14 Pages |
| (i) | Sole power to vote or to direct the vote – Each of HCVVIII, HCPVIII, HCP VIII LLC, Dr. Cavanaugh and Messrs. Werner, Littlechild and Lawlor have no power to vote or direct the vote of any shares of the Common Stock. Dr. Mirabelli has the sole power to vote or to direct the vote of 3,813 shares of the Common Stock. |
| (ii) | Shared power to vote or to direct the vote – 0 |
| (iii) | Sole power to dispose or to direct the disposition of – Each of HCVVIII, HCPVIII, HCP VIII LLC, Dr. Cavanaugh and Messrs. Werner, Littlechild and Lawlor have no power to dispose of or direct the disposition of any shares of the Common Stock. Dr. Mirabelli has the sole power to dispose of or to direct the disposition of 3,813 shares of the Common Stock. |
| (iv) | Shared power to dispose or to direct the disposition of – 0 |
Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).
| Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
Not Applicable
| Item 7. | Identification and Classification of the Subsidiary Which Ac quired the Security Being Reported on By the Parent Holding Company. |
Not Applicable
| Item 8. | Identification and Classification of Members of the Group. |
Not Applicable
| Item 9. | Notice of Dissolution of Group. |
Not Applicable
| Item 10. | Certification |
Not Applicable.
| CUSIP No. 74373B109 | 13G | Page 13 of 14 Pages |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| March 10, 2017 | HealthCare Ventures VIII, L.P. | |
| By: its General Partner, HealthCare Partners VIII, L.P. | ||
| By: its General Partner, HealthCare Partners VIII, LLC | ||
| By: | /s/ Jeffrey Steinberg | |
| Jeffrey Steinberg, Administrative Officer | ||
| HealthCare Partners VIII, L.P. | ||
| By: its General Partner, HealthCare Partners VIII, LLC | ||
| March 10, 2017 | By: | /s/ Jeffrey Steinberg |
| Jeffrey Steinberg, Administrative Officer | ||
| HealthCare Partners VIII, LLC | ||
| By: | /s/Jeffrey Steinberg | |
| March 10, 2017 | Jeffrey Steinberg, Administrative Officer | |
| March 10, 2017 | /s/Jeffery Steinberg, Attorney-in-Fact |
| James H. Cavanaugh, Ph.D. | |
| March 10, 2017 | /s/Jeffrey Steinberg, Attorney-in-Fact |
| Christopher Mirabelli, Ph.D. | |
| March 10, 2017 | /s/Jeffrey Steinberg, Attorney-in-Fact |
| Harold R. Werner | |
| March 10, 2017 | /s/Jeffrey Steinberg, Attorney-in-Fact |
| John W. Littlechild | |
| March 10, 2017 | /s/Jeffrey Steinberg, Attorney-in-Fact |
| Augustine Lawlor |
| CUSIP No. 74373B109 | 13G | Page 14 of 14 Pages |
EXHIBIT A
AGREEMENT
JOINT FILING OF SCHEDULE 13G
The undersigned hereby agree to jointly prepare and file with regulatory authorities a Schedule 13G and any future amendments thereto reporting each of the undersigned’s ownership of securities of Proteostasis Therapeutics, Inc. and hereby affirm that such Schedule 13G is being filed on behalf of each of the undersigned.
| March 10, 2017 | HealthCare Ventures VIII, L.P. | |
| By: its General Partner, HealthCare Partners VIII, L.P. | ||
| By: its General Partner, HealthCare Partners VIII, LLC | ||
| By: | /s/ Jeffrey Steinberg | |
| Jeffrey Steinberg, Administrative Officer | ||
| HealthCare Partners VIII, L.P. | ||
| By: its General Partner, HealthCare Partners VIII, LLC | ||
| March 10, 2017 | By: | /s/ Jeffrey Steinberg |
| Jeffrey Steinberg, Administrative Officer | ||
| HealthCare Partners VIII, LLC | ||
| March 10, 2017 | By: | /s/Jeffrey Steinberg |
| Jeffrey Steinberg, Administrative Officer | ||
| March 10, 2017 | /s/Jeffery Steinberg, Attorney-in-Fact | |
| James H. Cavanaugh, Ph.D. | ||
| March 10, 2017 | /s/Jeffrey Steinberg, Attorney-in-Fact | |
| Christopher Mirabelli, Ph.D. | ||
| March 10, 2017 | /s/Jeffrey Steinberg, Attorney-in-Fact | |
| Harold R. Werner | ||
| March 10, 2017 | /s/Jeffrey Steinberg, Attorney-in-Fact | |
| John W. Littlechild | ||
| March 10, 2017 | /s/Jeffrey Steinberg, Attorney-in-Fact | |
| Augustine Lawlor | ||